Japan· JP-4291477D2025
タルラタマブ（遺伝子組換え）
A tarlatamab product containing タルラタマブ（遺伝子組換え）, registered in Japan by アムジェン, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Tarlatamab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX33 (tarlatamab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Tarlatamab · ATC L01FX33
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- タルラタマブ（遺伝子組換え）
- Manufacturer
- アムジェン
- Country
- Japan (JP)
- ATC code
- L01FX33
- ATC class
- Tarlatamab
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tarlatamab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenIMDYLLTRA 1 mg Pulver till koncentrat och lösning till infusionsvätska, lösningAmgen Europe B.V.
- CanadaIMDELLTRAAMGEN CANADA INC
- SwitzerlandImdylltra 1 mg, Pulver für ein Konzentrat und Stabilisatorlösung zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaIMDYLLTRAAmgen Europe B.V., Breda
- SpainIMDYLLTRA 1 MG POLVO PARA CONCENTRADO Y SOLUCIÓN PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandImdylltraAmgen Europe B.V.
- FranceIMDYLLTRA 1 mg, poudre pour solution à diluer et solution pour solution pour perfusionAMGEN EUROPE
- United KingdomImdylltra 10mg powder for concentrate and solution for solution for infusion vialsAmgen Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Imdylltra
- Norway · Imdylltra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/005885b9-f57e-41e3-ac9f-10844dca40f0 GET /v1/drugs/005885b9-f57e-41e3-ac9f-10844dca40f0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１０ｍｇ１瓶（輸液安定化液付）",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291477D2025",
"category": "注射薬",
"price_yen": 1360042,
"generic_name": "タルラタマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about tarlatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.